Men with prostate cancer have a major decision to make: whether to get a lifesaving surgery. Radical prostatectomy, the ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical study) procedure on the East Coast using the Vanquish(R) ...

A preclinical evaluation of a new 'dual-mode' tracer agent shows promise in not only helping surgeons image and plan prostate cancer procedures, but also provide them with much more consistent and ...

A new, pioneering procedure was used to treat a record number of prostate patients in a day. Frimley Health NHS Foundation trust were able to break their record thanks to the use of a robot-assisted ...

New findings from the phase III PRIMARY2 trial presented at EAU26 suggest that PSMA PET/CT imaging after inconclusive or reassuring MRI can safely reduce prostate biopsies by about 50 percent without ...

A preclinical evaluation of a new ’dual-mode’ tracer agent shows promise in not only helping surgeons image and plan prostate cancer procedures, but also provide them with much more consistent and ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major advancement in image-guided navigation for prostate cancer care with ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm. The post New state-of-the-art test identifies ...